Literature DB >> 31174860

Single-Center Analysis of the Potential Inappropriate Use of Intravenous Medications in Hospitalized Patients in China.

Shuangshuang Zeng1, Dong Wang2, Yuanliang Yan1, Minwen Zhu1, Wanli Liu3, Zhicheng Gong4, Ling Wang5, Shusen Sun6.   

Abstract

This study categorizes the types of inappropriate intravenous prescriptions in hospitalized patients in China. Prescription data from 2016 were retrospectively analyzed based on predefined categories of inappropriateness. Of the 123,521 patients included, 89.2% received intravenous medications, contributing to 80% of the patients' hospital medication costs. Of significant concern, antibiotics and traditional Chinese medicines were administered to 44.3% and 14.5% of hospitalized patients, respectively. Overall, 11.4% of all intravenous prescriptions were classified as inappropriate, with improper diluent and diluent volumes being the primary cause. A team-based collaborative approach is necessary to address this widespread issue in China.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31174860     DOI: 10.1016/j.clinthera.2019.05.009

Source DB:  PubMed          Journal:  Clin Ther        ISSN: 0149-2918            Impact factor:   3.393


  4 in total

Review 1.  Overuse of intravenous infusions in China: focusing on management platform and cultural problems.

Authors:  Shuangshuang Zeng; Dong Wang; Wanli Liu; Yuanliang Yan; Minwen Zhu; Zhicheng Gong; Shusen Sun
Journal:  Int J Clin Pharm       Date:  2019-08-30

2.  Recent initiatives to enhance the safety of intravenous medications in Chinese hospitals.

Authors:  Shusen Sun
Journal:  Eur J Hosp Pharm       Date:  2020-08-28

3.  Development and Evaluation of an Intravenous Infusion Sequence Annotation System.

Authors:  Ji Qiu; Tingting Deng; Zhuo Wang; Zhangwei Yang; Ting Liu; Yunjie Liu; Rui Li; Fu Dai
Journal:  Appl Clin Inform       Date:  2021-02-03       Impact factor: 2.342

Review 4.  Applying artificial intelligence for cancer immunotherapy.

Authors:  Zhijie Xu; Xiang Wang; Shuangshuang Zeng; Xinxin Ren; Yuanliang Yan; Zhicheng Gong
Journal:  Acta Pharm Sin B       Date:  2021-02-11       Impact factor: 11.413

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.